Review: SGLT2 Inhibitors as a Potential Treatment for Alport Syndrome

In this review, the authors discuss sodium-glucose co-transporter-2 (SGLT2) inhibitors as a potential treatment in Alport syndrome, a rare genetic disease characterized by kidney disease and ocular and auditory defects. There is no cure but therapeutic blockade of the renin-angiotensin-aldosterone system can slow the progression of end-stage kidney disease (ESKD).

Recent clinical trials in chronic kidney disease have shown good cardiovascular and renal outcomes in patients with diabetes mellitus treated with SGLT2 inhibitors. SGLT2 inhibitors have been found to have additional nephroprotective properties which make them a potential treatment option in progressive kidney disease.

Read the full abstract here.

Reference

Mabillard H and Sayer JA. SGLT2 inhibitors – a potential treatment for alport syndrome. Clin Sci (Lond). 2020;134(4):379-388. DOI: 10.1042/CS20191276